PROTOCOL,PUB_ID,RX_CODE,RX_LABEL,AGE,AGEGR1,SEX,GENDER,RACE,HISPANIC,DISC_FL,DISC_RSN,EARLY_TERM_FL,TERM_RSN,TERM_AE,NUM_VAC_RECD
107,107-001,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",20,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-002,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",25,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-003,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,Yes,HIV infection,No,5
107,107-004,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",37,31 - 40,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-005,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",19,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,3
107,107-006,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",20,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-007,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",30,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-008,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",18,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-009,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",28,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-010,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",19,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-011,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-012,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",19,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-013,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",19,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-014,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-015,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-016,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,3
107,107-017,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",18,18 - 20,Female,Female,Black/African American,No,Yes,Unable to contact,Yes,Participant refused further participatio,No,2
107,107-018,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-019,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,Yes,Unable to contact,Yes,Unable to contact participant,No,1
107,107-020,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",28,21 - 30,Female,Female,Black/African American,No,,,Yes,Participant unable to adhere to visit sc,No,5
107,107-021,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",28,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-022,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",21,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-023,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",22,21 - 30,Male,Male,Black/African American,No,Yes,HIV infection,Yes,HIV infection,No,3
107,107-024,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",27,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-025,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",36,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-026,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",33,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-027,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",34,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-028,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",25,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,3
107,107-029,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",28,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-030,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-031,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",21,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-032,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",22,21 - 30,Female,Female,Black/African American,No,,,Yes,Participant refused further participatio,No,5
107,107-033,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",35,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-034,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",28,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-035,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-036,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",21,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-037,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,Yes,Unable to schedule,Yes,Participant refused further participatio,No,3
107,107-038,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",38,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-039,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-040,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-041,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",29,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-042,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",27,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-043,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",29,21 - 30,Male,Male,Black/African American,No,Yes,Other,No,Scheduled exit visit/end of study,No,1
107,107-044,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",20,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-045,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",39,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-046,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",25,21 - 30,Male,Male,Black/African American,No,Yes,Other clinical event,No,Scheduled exit visit/end of study,No,2
107,107-047,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",29,21 - 30,Female,Female,Black/African American,No,Yes,HIV infection,Yes,HIV infection,No,2
107,107-048,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",21,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-049,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",37,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-050,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",19,18 - 20,Female,Female,Black/African American,No,Yes,Unable to contact,Yes,Unable to contact participant,No,3
107,107-051,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",30,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-052,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,Yes,Other clinical event,No,Scheduled exit visit/end of study,No,3
107,107-053,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",19,18 - 20,Male,Male,Black/African American,No,Yes,Refused,Yes,Participant refused further participatio,No,1
107,107-054,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",20,18 - 20,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-055,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",30,21 - 30,Male,Male,Black/African American,No,Yes,Unable to contact,Yes,Unable to contact participant,No,3
107,107-056,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",27,21 - 30,Female,Female,Black/African American,No,Yes,HIV infection,Yes,HIV infection,No,3
107,107-057,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-058,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",31,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-059,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",30,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-060,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",29,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-061,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-062,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-063,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",21,21 - 30,Male,Male,Black/African American,No,,,Yes,Participant incarcerated,No,5
107,107-064,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Female,Female,Black/African American,No,Yes,Other,Yes,Participant refused further participatio,No,2
107,107-065,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",25,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-066,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",22,21 - 30,Female,Female,Black/African American,No,Yes,Refused,Yes,Participant refused further participatio,No,4
107,107-067,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",18,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-068,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",27,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-069,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",22,21 - 30,Female,Female,Black/African American,No,Yes,HIV infection,Yes,HIV infection,No,1
107,107-070,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",25,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-071,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",31,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-072,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-073,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-074,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",20,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-075,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Female,Female,Black/African American,No,Yes,Refused,Yes,Participant refused further participatio,No,1
107,107-076,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-077,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",30,21 - 30,Female,Female,Black/African American,No,Yes,Other,Yes,"Investigator decision, specify",No,2
107,107-078,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-079,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-080,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-081,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",20,18 - 20,Male,Male,Black/African American,No,,,Yes,Unable to contact participant,No,5
107,107-082,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-083,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",19,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-084,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,Yes,Refused,No,Scheduled exit visit/end of study,No,4
107,107-085,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-086,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",39,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-087,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-088,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",34,31 - 40,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-089,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",29,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-090,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",27,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-091,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-092,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",23,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-093,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-094,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-095,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",19,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-096,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",23,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-097,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",25,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-098,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-099,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",26,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-100,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-101,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",37,31 - 40,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-102,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",30,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-103,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",29,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-104,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",20,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-105,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-106,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",25,21 - 30,Male,Male,Black/African American,No,,,Yes,"Participant relocated, no follow-up plan",No,4
107,107-107,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",21,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-108,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,Yes,Refused,Yes,Participant refused further participatio,No,2
107,107-109,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-110,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",19,18 - 20,Male,Male,Black/African American,No,,,Yes,Unable to contact participant,No,3
107,107-111,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",20,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-112,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",28,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-113,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",22,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-114,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-115,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",25,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,3
107,107-116,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",22,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-117,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",31,31 - 40,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-118,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",23,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-119,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-120,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",21,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-121,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",24,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-122,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",28,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-123,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,Yes,Participant unable to adhere to visit sc,No,5
107,107-124,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",30,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-125,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",26,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-126,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",27,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-127,T4,"ALVAC mo(0,1,3, 6,12) + Bivalent Subtype C gp120(3,6,12)",18,18 - 20,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-128,T1,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12)",24,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-129,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",25,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-130,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",21,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5
107,107-131,T3,"ALVAC mo(0,1,6,12) + Bivalent Subtype C gp120/MF59 mo(0,1,6,12)",30,21 - 30,Male,Male,Black/African American,No,,,No,Scheduled exit visit/end of study,No,4
107,107-132,T2,"ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12)",26,21 - 30,Female,Female,Black/African American,No,,,No,Scheduled exit visit/end of study,No,5